Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PCV-LITE in healthy adults
NCT06986239Phase 1Not yet recruiting
- Sponsor
- LiteVax BV
- Start
- Jul 2025
- Primary completion
- Apr 2026
- Modality
- Vaccines & Immunotherapeutics
01
Overview
Phase 1, randomised, single-blind trial of PCV-LITE in pneumococcal infection (4 arms), sponsored by LiteVax BV. Primary endpoint: Solicited and non-solicited local and systemic adverse events at 180 days. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
PCV-LITE
03
Conditions
pneumococcal infection
Beyond the preview
Go deeper on NCT06986239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06986239.